FAK inhibition in a pancreatic ductal carcinoma (PDAC) model promotes CD8+ cytotoxic T cell recruitment and creates a less fibrotic TME, rendering previously resistant PDAC cells sensitive to Gemcitabine, T cell therapy and PD1 agonists29. The gene discussed is CD8A; the disease is pancreatic ductal adenocarcinoma.